[Research Report] The lung cancer therapy market is expected to grow from US$ 31,018.32 million in 2022 to US$ 80,493.84 million by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.
Market Insights and Analyst View:
The lung cancer therapy market size is expanding with the rising cases of lung cancer, and the increasing habit of smoking and tobacco consumption in countries such as the UK, Germany, the US, and India. ~48,000 people get diagnosed with lung cancer, and ~35,000 people die yearly because of the disease in the UK. Smoking is the most common cause of lung cancer, while other causes include passive smoking and exposure to certain gases and chemicals. Currently, every fourth man (~27.0%) and every fifth woman (~21%) in Germany smokes regularly. The current landscape for lung cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple lung cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the lung cancer therapy market
Growth Drivers and Challenges:
Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally, lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths worldwide, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020.
According to the American Cancer Society’s estimates for lung cancer in the US, ~238,340 new lung cancer cases are likely to be registered in 2023, including 120,790 women and 117,550 men. Also, according to the National Center for Biotechnology Information (NCBI), ~41,000 new diagnoses of lung cancers and ~34,000 deaths are recorded yearly in Italy. As per the Cancer Australia 2023 report, ~14,529 new lung cancer cases were diagnosed in 2022, which included 7,707 males and 6,822 females. Nearly 9% of new cancer cases were diagnosed in 2022, with an estimated 8,664 deaths. Data provided by the Health Ministry of Turkey states that ~23,000 men and ~4,500 women are diagnosed with lung cancer annually in Turkey. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.
Since 1995, there has been a marked increase in the prices of new cancer drugs due to the acceptance of biologics in of biologics in oncology. In the US, the monthly cost incurred for the treatment of cancer is ~US$ 100,000. Cancer drug prices are the highest in the country; the drugs are more than two-fold costlier than those in Europe and two- to six-times more expensive than those in the rest of the world. The cost of lung cancer treatments in a few of the countries is given below:
Country | Range of Treatment Cost |
India | INR 100,000–2,00,000 (US$ 1,203.01–2,406.02) |
US | US$ 25,000 to US$ 50,000 |
Nigeria | ₦5,540,000–9,000,000 (US$ 721.56–1,172.2) |
Kenya | KES.100,000–300,000 (US$ 668.22–2,004.66) |
Ghana | GHS 80,000–2,00,000 (US$ 6,823.44–17,058.6) |
Turkey | Liras 180,000–22,000 (US$ 6,512–7,959.12) |
Germany | €18,000–25,000 (US$ 19,046.5–26,453.5) |
The monthly cost of many anticancer drugs greatly exceeds most household incomes. Thus, there is a huge pressure on researchers to limit costs and demonstrate value. Political uncertainty and persistent economic stress in many countries are raising concerns about the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective drugs influences the health conditions of populations, resulting in a low average life expectancy. In countries without universal healthcare and healthcare coverage providers, patients have to pay out-of-pocket for their treatments. The high costs associated with drugs are limiting the revenues of oncology drug manufacturers by limiting their access to only the wealthy population and people who have effective insurance coverage. Thus, the high cost of drugs and surgeries hampers the lung cancer therapy market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Lung Cancer Therapy Market: Strategic Insights
Market Size Value in US$ 31,018.32 million in 2022 Market Size Value by US$ 80,493.84 million by 2030 Growth rate CAGR of 12.7% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Lung Cancer Therapy Market: Strategic Insights
| Market Size Value in | US$ 31,018.32 million in 2022 |
| Market Size Value by | US$ 80,493.84 million by 2030 |
| Growth rate | CAGR of 12.7% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others. Based on geography, the lung cancer therapy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Segmental Analysis:
The lung cancer therapy market, by vaccine type, is segmented into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the noninvasive therapy segment held a larger market share. The minimally invasive segment is expected to record a higher CAGR during 2022–2030. Radiation therapy, chemotherapy, and targeted therapy are the major types of noninvasive lung cancer therapies. Radiation lung cancer therapy uses high energy and powerful X-rays to eliminate the cancerous cells, control their growth, and stop their spread within the lungs. Radiation therapy is used before and after surgeries to shrink the tumor before surgery and kill the persistent cancer cells after surgeries. In chemotherapy, drugs are used to kill the new or existing cancerous cells in the lungs. Chemotherapy is considered an important treatment for lung cancer. According to the article “Chemotherapy Statistics” published in 2023, approximately 2% of stage 1 and 2 patients, 9% of stage 3 patients, and 27% of stage 4 patients receive chemotherapy for treatment of their lung cancer, respectively.
The minimally invasive segment is further segmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. Photodynamic ablation is an underutilized therapy that leads to the selective destruction of cancer cells by the production of reactive oxygen. This type of therapy has been extensively studied clinically as well as in in-vitro environments. Various research studies have been conducted for checking the efficacy of photodynamic ablation therapy in combination with nanoparticles in lung cancer patients.
Radiofrequency ablation (RFA) is the latest and most promising treatment for cancer patients, including inoperable NSCLC patients. With high feasibility and safety, RFA can cause irreversible injury or coagulation necrosis to tumors by utilizing the biological effects of heat. In recent years, more hospitals have started choosing RFA rather than stereotactic body radiotherapy (SBRT) as a nonsurgical treatment option for early-diagnosed NSCLC. Thus, increasing research activities in photodynamic ablation therapy and a growing preference for radiofrequency ablation therapy are fueling the growth of the lung cancer therapy market for the RFA segment. The microwave ablation technique uses a thin needle to transmit microwaves into liver tumors to destroy cancer cells with heat.
Chemical ablation is the technique in which a chemical mixture is injected into the vein, followed by observing it using ultrasound imaging. The application and combination of different drugs, from anhydrous ethanol and glacial acetic acid to epi-amycin, have been clinically tested for a long time.
Regional Analysis:
Based on geography, the lung cancer therapy market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the growth of the global lung cancer therapy market. Asia Pacific is expected to register the highest CAGR in the lung cancer therapy market during 2022–2030. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.
Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. In May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy approved for tumors with KRAS mutation, which accounts for ~25% of the mutations reported in non-small cell lung cancer (NSCLC) cases. In May 2021, the US FDA granted accelerated approval to Rybrevant (amivantamab-vmjw), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors in adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.
Lung Cancer Therapy Market Report Scope
Industry Developments and Future Opportunities:
Various initiatives by key players operating in the Lung Cancer Therapy Market are listed below:
- In October 2023, Johnson & Johnson submitted the Type II extension of indication application seeking approval of the European Medicines Agency (EMA) for the use of RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed) as the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
- In December 2022, RF Medical Co Ltd announced that the FDA approved their patented MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system for commercialization in the US. These devices are used to treat damaged tumors and tissues.
- May 2021, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The drug is indicated among patients showing disease progression on or after platinum-based chemotherapy. RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.
Competitive Landscape and Key Companies:
A few of the prominent players operating in the lung cancer therapy market are Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Therapy Type, Indication, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The lung cancer therapy market is analyzed on the basis of disease indication, type, offering, technology, and end user. Based on therapy type, the lung cancer therapy market is segmented into non-invasive and minimally invasive. Minimally Invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the noninvasive therapy segment held a larger market share. The minimally invasive segment is expected to record a higher CAGR during 2022–2030.
The lung cancer therapy market majorly consists of the players such Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp among others.
The increasing cases of lung cancer, and government initiatives for the screening and treatment of lung cancer bolster the lung cancer therapy market size. However, the high cost of lung cancer therapy hinders the lung cancer therapy market growth.
The most common treatment for lung cancer includes surgery, radiotherapy, chemotherapy, and immunotherapy. Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Lung Cancer Therapy Market, by Geography
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Lung Cancer Therapy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Lung Cancer Therapy Market - Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Increase in Cases of Lung Cancer
5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:
6. Lung Cancer Therapy Market - Global Market Analysis
6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
7. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
7.3.1 Overview
7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
7.4.1 Overview
7.4.2 Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
8. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
8.3.1 Overview
8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
8.4.1 Overview
8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
9.4.1 Overview
9.4.2 Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
9.5.1 Overview
9.5.2 Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. Lung Cancer Therapy Market - Geographical Analysis
10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Lung Cancer Therapy Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Lung Cancer Therapy Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.6 Russia
10.2.6.6.1 Overview
10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6 Southeast Asia
10.3.6.6.1 Overview
10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.6 Singapore
10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.7 Malaysia
10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.8 Indonesia
10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.9 Vietnam
10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.10 Cambodia
10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.11 Philippines
10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.12 Rest of Southeast Asia
10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Lung Cancer Therapy Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
11. Lung Cancer Therapy Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Medtronic Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 RF Medical Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Merck KGaA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bioventus Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olympus Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Advanz Pharma Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
List of Tables
Table 1. Lung Cancer Therapy Market Segmentation
Table 2. Global Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Lung Cancer Therapy Market, by Therapy Type– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. US Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 10. US Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 25. UK Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 26. UK Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 31. France Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. France Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 33. France Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 34. France Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 43. Russia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Russia Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 45. Russia Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 46. Russia Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Europe Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Europe Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 52. Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 53. Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 54. Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 55. China Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. China Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 57. China Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 58. China Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 60. Japan Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 61. Japan Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 62. Japan Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 63. India Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. India Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 65. India Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 66. India Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 67. Australia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Australia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 69. Australia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 70. Australia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 71. South Korea Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 72. South Korea Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 73. South Korea Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 74. South Korea Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 75. Southeast Asia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 76. Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 77. Southeast Asia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 78. Southeast Asia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 79. Singapore Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 80. Singapore Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 81. Singapore Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 82. Singapore Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 83. Malaysia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 84. Malaysia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 85. Malaysia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 86. Malaysia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 87. Indonesia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 88. Indonesia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 89. Indonesia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 90. Indonesia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 91. Vietnam Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 92. Vietnam Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 93. Vietnam Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 94. Vietnam Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 95. Cambodia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 96. Cambodia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 97. Cambodia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 98. Cambodia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 99. Philippines Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 100. Philippines Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 101. Philippines Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 102. Philippines Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 103. Rest of Southeast Asia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 104. Rest of Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 105. Rest of Southeast Asia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 106. Rest of Southeast Asia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 107. Rest of Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 108. Rest of Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 109. Rest of Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 110. Rest of Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 111. Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 112. Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 113. Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 114. Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 115. Saudi Arabia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 116. Saudi Arabia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 117. Saudi Arabia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 118. Saudi Arabia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 119. South Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 120. South Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 121. South Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 122. South Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 123. UAE Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 124. UAE Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 125. UAE Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 126. UAE Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 127. Rest of Middle East Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 128. Rest of Middle East Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 129. Rest of Middle East Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 130. Rest of Middle East Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 131. South & Central America Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 132. South & Central America Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 133. South & Central America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 134. South & Central America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 135. Brazil Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 136. Brazil Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 137. Brazil Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 138. Brazil Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 139. Argentina Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 140. Argentina Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 141. Argentina Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 142. Argentina Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 143. Rest of South & Central America Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 144. Rest of South & Central America Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 145. Rest of South & Central America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 146. Rest of South & Central America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 147. Recent Inorganic Growth Strategies in the Lung Cancer Therapy Market
Table 148. Recent Organic Growth Strategies in Lung Cancer Therapy Market
Table 149. Glossary of Terms, Lung Cancer Therapy Market
List of Figures
Figure 1. Lung Cancer Therapy Market Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Lung Cancer Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
Figure 6. Lung Cancer Therapy Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 8. Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 14. Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America: Lung Cancer Therapy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Europe Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 25. Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 27. UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Asia Pacific Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 35. Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Asia Pacific Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 37. China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. Middle East & Africa Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 52. Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Middle East & Africa Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 54. Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. South & Central America Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 59. South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. South & Central America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 61. Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 62. Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 63. Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Growth Strategies in Lung Cancer Therapy Market
The List of Companies - Lung Cancer Therapy Market
- Medtronic PLC
- RF Medical Co Ltd
- Johnson & Johnson
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
- Bioventus Inc
- Meiji Seika Pharma Co Ltd
- Advanz Pharma Corp
- Olympus Corp
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Lung Cancer Therapy Market
Oct 2023
Laser-Assisted ENT Surgeries Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Laser Type (C02 Laser, Nd:YAG Laser, Diode Laser, Blue Laser, KTP Laser, Argon Laser, and Other Laser Types), Surgery Type [Laser Laryngeal Surgery, Laser Endoscopic Sinus Surgery (LESS), Laser-Assisted Uvulopalatoplasty (LAUP), Laser-Assisted Stapedotomy, Laser-Assisted Tonsillectomy and Adenoidectomy, Laser Turbinates Reduction, Transoral Laser Microsurgery (TLM), Nasal Surgery, and Other Surgery Types], End User (Hospitals and Specialty Clinics, Physician Offices, and Other End Users), and Geography (North America, Europe, Asia Pacific, South and Central America, and Middle East and Africa)
Oct 2023
Mobile Cleanroom Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Softwall and Hardwall), End User (Microelectronics Industry, Pharmaceuticals and Biotechnology Industry, Medical Device Manufacturers, and Others), and Geography
Oct 2023
Ovo-Sexing Technology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique (Non-Invasive Imaging, Genetic Editing, Volatile Analysis, Sex Reversal, and Liquid-Based Analysis), End User (Hatcheries and Poultry Farms), and Geography (US, Germany, France, Italy, Spain, Rest of Europe, Israel, and ROW)
Oct 2023
Dental Laser Treatment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Hard Tissue, Soft Tissue, and Others), End User (Hospitals, Dental Clinics, Dental-Owned Practices, and Others), Clinical Indication [Conservative Dentistry, Root Canal (Endodontic Treatment), Oral Surgery, Implantology, Peri-Implantitis, Periodontics, and Others], and Geography
Oct 2023
Microbiology CRO Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Clinical, Medical Device, and Others), Service Type (Assay Development, Custom Viral Stock Production, Microbial Testing, and Others), Microorganisms (Bacteria, Fungi, Viruses, and Parasites), End User (Biotech and Pharmaceutical Companies, Medical Device Companies, and Others), and Geography
Oct 2023
Antimicrobial Surgical Suture Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Triclosan Antimicrobial Suture and Chlorhexidine Antimicrobial Suture), Raw Materials (Polyglactin 910 Antimicrobial Suture, Poliglecaprone 25, and Polyglycolic Acid), Application (Cardiovascular Surgery, General Surgery, Ophthalmic Surgery, Gynecological Surgery, Orthopedic Surgery, Plastic Surgery, Veterinary Surgery, Dental Surgery, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2023
Fall Management Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sensor Pads, Floor Mat, Hip Protectors, Alert Systems, Communication Devices, and Other Products), Application (Fall Detection Systems, Fall Prevention Equipment, and Post-Fall Monitoring and Response Systems), Age Group [Elderly Population (65 and Above) and Adults (18–64 years)], End User (Hospitals and Clinics, Nursing Homes, Home Care Settings, and Other End Users), and Geography
Oct 2023
Organoids Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology Disease, Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ Specific Adult Stem Cell), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Get Free Sample For